"Leucovorin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS.
Descriptor ID |
D002955
|
MeSH Number(s) |
D03.633.100.733.631.400.800.350.450 D08.211.840.300.500
|
Concept/Terms |
Leucovorin- Leucovorin
- Folinic Acid-SF
- Folinic Acid SF
- Leukovorin
- Leukovorum
- Folinic Acid
- Acid, Folinic
Citrovorum Factor- Citrovorum Factor
- Factor, Citrovorum
- Calcium Leucovorin
- Leucovorin, Calcium
- Calcium Folinate
- Folinate, Calcium
N(5)-Formyltetrahydrofolate- N(5)-Formyltetrahydrofolate
- 5-Formyltetrahydropteroylglutamate
- 5 Formyltetrahydropteroylglutamate
- 5-Formyltetrahydrofolate
- 5 Formyltetrahydrofolate
|
Below are MeSH descriptors whose meaning is more general than "Leucovorin".
Below are MeSH descriptors whose meaning is more specific than "Leucovorin".
This graph shows the total number of publications written about "Leucovorin" by people in this website by year, and whether "Leucovorin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 3 | 5 |
1995 | 2 | 3 | 5 |
1996 | 3 | 1 | 4 |
1997 | 3 | 3 | 6 |
1998 | 1 | 5 | 6 |
1999 | 2 | 2 | 4 |
2000 | 1 | 5 | 6 |
2001 | 2 | 4 | 6 |
2002 | 0 | 3 | 3 |
2003 | 0 | 6 | 6 |
2004 | 2 | 6 | 8 |
2005 | 1 | 2 | 3 |
2006 | 0 | 4 | 4 |
2007 | 0 | 4 | 4 |
2008 | 0 | 6 | 6 |
2009 | 0 | 5 | 5 |
2010 | 0 | 5 | 5 |
2011 | 0 | 5 | 5 |
2012 | 0 | 8 | 8 |
2013 | 1 | 2 | 3 |
2014 | 0 | 6 | 6 |
2015 | 0 | 3 | 3 |
2016 | 1 | 2 | 3 |
2017 | 1 | 7 | 8 |
2018 | 1 | 6 | 7 |
2019 | 0 | 3 | 3 |
2020 | 0 | 11 | 11 |
2021 | 0 | 4 | 4 |
2022 | 0 | 7 | 7 |
2023 | 0 | 4 | 4 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leucovorin" by people in Profiles.
-
Impact of a non-therapeutic laparotomy in patients with locally advanced pancreatic cancer treated with induction (m)FOLFIRINOX: Trans-Atlantic Pancreatic Surgery (TAPS) Consortium study. Br J Surg. 2024 Mar 02; 111(3).
-
Serum CEA as a Prognostic Marker for Overall Survival in Patients with Localized Pancreatic Adenocarcinoma and Non-Elevated CA19-9 Levels Treated with FOLFIRINOX as Initial Treatment: A TAPS Consortium Study. Ann Surg Oncol. 2024 Mar; 31(3):1919-1932.
-
Preoperative Treatment of Locally Advanced Rectal Cancer. N Engl J Med. 2023 Jul 27; 389(4):322-334.
-
Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023 07 20; 41(21):3724-3734.
-
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. JAMA Netw Open. 2023 06 01; 6(6):e2316161.
-
FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Ann Surg Oncol. 2023 Jul; 30(7):4417-4428.
-
Adjuvant 5-Fluorouracil/leucovorin, capecitabine, and oxaliplatin-related regimens for stage II/III colon cancer patients 66?years or older. Cancer Med. 2023 02; 12(3):2389-2406.
-
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 09 01; 8(9):1263-1270.
-
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. J Natl Compr Canc Netw. 2022 07; 20(7):783-791.e1.
-
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. J Natl Cancer Inst. 2022 05 09; 114(5):695-703.